Quarterly guidance

Revenue
Approximately $18.4 billion
Adjusted EPS
$3.83 to $3.87

Annual guidance

Adjusted EPS
$13.95 to $13.99
Total net revenues
Approximately $67.8 billion
Immunology revenue
$34.9 billion
Neuroscience revenue
$13 billion
Oncology revenue
$6.6 billion
Aesthetics revenue
$5 billion

Outlook

Immunology growth
Management expects SKYRIZI and RINVOQ to continue delivering robust growth, supported by new indications and subcutaneous induction options.
Neuroscience momentum
The company anticipates continued strong demand for VRAYLAR, Ubrelvy, Qulipta, and BOTOX Therapeutic.
Parkinson's portfolio
The company expects its Parkinson's therapies, including JUVMO and V11, to collaboratively deliver peak sales of more than $5 billion.
Oncology pipeline
Management anticipates regulatory approvals for atensimig in 2027 and expects EPLINLY to become a new standard of care in frontline DLBCL.
Aesthetics recovery
While the category has faced pressure, management is seeing signs of stability and expects innovation like BOE to drive new patient initiation.
Capital allocation
The company remains committed to a growing dividend and maintaining a net leverage ratio of 2x over the next 2 to 3 years.
Obesity strategy
AbbVie is actively looking to expand its obesity portfolio with differentiated assets that prioritize tolerability.
IRA impact
Management noted that IRA price negotiations will begin in 2027 and should be factored into models.